Navigation Links
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Date:8/7/2008

as a service for its research customers. Inovio will receive a royalty on such services.

Subsequent to the quarter, we announced the signing of a definitive merger agreement with VGX Pharmaceuticals, Inc., a privately-held DNA vaccine developer, which provides for the issuance of Inovio Biomedical securities in exchange for all of the outstanding securities of VGX Pharmaceuticals, subject to completion of the registration of the Inovio Biomedical securities to be issued with the U.S. Securities and Exchange Commission (SEC), receipt of approval from both companies' stockholders of the transaction, listing approval from the American Stock Exchange and other customary closing conditions. The parties expect to complete the merger in the fourth quarter of 2008, however, the actual timing of the transaction will depend on a number of factors, some of which are beyond either company's control.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX: INO) is focused on developing multiple DNA-based immunotherapies and DNA vaccines. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Human data has shown that Inovio's electroporation-based DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology, our operatio
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results 
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... Small print and poor printing on prescription labels ... may lead to errors in taking medication, according ... and CNIB (Canadian National Institute for the Blind)., ... Pharmacists Journal , found that labels on prescription ... professionally recommended guidelines for legibility. , By simply ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... only soybean oil to provide the highest level of ... clean taste., IOWA CITY, Iowa, Feb. 12 An ... only meets the increasing,consumer demand for low trans fat foods, ... so important to food processors., Asoyia Mid Oleic Ultra ...
... N.J., Feb. 12 TeamStaff, Inc.,(Nasdaq: ... and administrative,staffing services, announced today that it ... division, RS Staffing Services, Inc., to TeamStaff,Government ... Georgia based subsidiary currently provides medical, office,administration ...
... Should be considered along with LDL cholesterol ... 12 (HealthDay News) -- A new study showing ... of cardiac trouble strengthens the case for including ... , "Triglycerides traditionally have been viewed as second-class ...
... the recent announcement by,the United States Food and Drug ... Cosmetic (botulinum toxin type A), customers are,looking for alternatives ... FDA approval in 2002 for the temporary treatment of,moderate ... 18 to 65 years,of age. In its recent communication, ...
... DALLAS, Feb. 12 The Beryl Companies announced ... president of product management,and marketing. In this newly ... at a time when new services are being ... strategies., "Mark is a welcome addition to ...
... Association Join Forces to,Educate, African-Americans on Managing ... Feb. 12 A recent survey,commissioned by the ... among African-Americans, two out of three (61,percent) expressed ... of,five (40 percent) expressed concern about developing Alzheimer,s. ...
Cached Medicine News:Health News:Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Triglycerides Linked to Coronary Disease Risk 2Health News:Triglycerides Linked to Coronary Disease Risk 3Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 4
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... for Tuesday, December 9 at 11:00 am ET to Discuss ... , SOUTH SAN FRANCISCO, Calif., Dec. ... SNSS ), a biopharmaceutical company focused on the development and ... its studies of voreloxin in acute myeloid leukemia (AML) will ...
... 1 Vical Incorporated (Nasdaq: VICL ) announced ... Merck & Co., Inc. based on Merck,s planned initiation of ... (pDNA) cancer vaccine. The candidate vaccine is based on Vical,s ... (hTERT). hTERT is the subject of separate license agreement. , ...
Cached Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
... The Sidekick Testing System is the smallest ... System is there when you need it ... or suitcase, or simply in your purse or ... take wherever you go. And, because it's so ...
Inquire...
Inquire...
... Tube is a cost-effective method of providing ... your patient. The warming tube is ideal ... Cath. Lab., and Radiology. The CSZ Warming ... warm patients since it may be used ...
Medicine Products: